Private Capital in the Neurosciences… is Overdue

Hello Friends, Visitors and the Curious,

In this my third and final post for “Neurosciences – Need is Growing, but not Investments: sub-titled: “Private Capital in the Neurosciences… is Overdue”

I am deeply flattered that my first Linkedin post is now at 1,229 views and my second at nearly 3,000! A big thank you to all that took the time to read my work.

In this release, I discuss the complexities of investing in the neuro-device space. It is not for the faint of heart. That said, complexity also scares away competition. My father advised, “look for the un-swept corner then clean up”. I think I have successfully made the case that there is a significant unmet need in the neurosciences, i.e., the need for objective measurement tool(s), ones with high sensitivity and properly matched specificity, that can: provide early detection, map the natural history of a disease, and monitor the effectiveness of any drug regimen.

There are solutions to fill the need, and, as a result, money to be made.  Success, however, requires leadership, solid analytics, and capital to clean up this corner. Money will be made by someone.

Please read. I welcome your comments and feedback either here or to my email jhschroeder2@rzacquisition.com.

Thank you for your interest in this important topic.

Best,
Howison Schroeder
July 22, 2021
Note: My two previous releases were published as “posts” on Linkedin. I have since learned that by publishing an “article” on Linkedin, I get more analytics for much longer (2years) rather than a few months. I hope this did not/ does not cause confusion. JHS

Why do Neuro Drug Trials/ Studies Fail?

Neurologic evaluations remain highly subjective in a time of transformative digital advances. The big unmet need for the neurosciences is a practical tool that provides highly sensitive, objective neuro-functional data. Given the poor track record of FDA approvals for neuro-drugs, one would think the drug companies would be at the front of the line to fund such advances. The reality, however, is that companies with or close to a solution are starving for capital.

As before, feel free to head to my website https://rzacquisition.com/ where both Post #1 & 2 of the, "Neurosciences –Need is Growing, but not Investments", can be found. Post #3 will be next week.

Thank you for your interest and please feel free to comment.

J Howison Schroeder

Neurology- The new Oncology?

Cancers are being cured, heart disease is being addressed, and we are living longer. So, what is the next medical frontier we need to conquer? Neurology, our own brains.

• “The burden of almost all neurological disorders increased from 1990 to 2017” JAMA Neurologic Disorders Article (JAMA Neurol. 2021;78(2):165-176. doi:10.1001/jamaneurol.2020.4152).
• “The number of people diagnosed with PD (Parkinson’s Disease) increases with age.” (Parkinson's Statistics).
• Traumatic Brain Injuries (TBI), aka concussions, impact our younger population. Multiple, repetitive sports concussions can lead to neurologic issues later in life. Concussions have generated prominent headlines for the last 15 years.

So, is “Neurology is the new oncology?”, as Harris Kaplan, a highly respected medical strategy consultant, recently declared?